Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME G DEVILLE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1750301503
CMS profile
306772
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$12,707.12

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $11,000.00 2
Travel and Lodging $1,225.47 5
Food and Beverage $481.65 6

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $11,468.52 9
Astellas Pharma US Inc $1,238.60 4

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME G DEVILLE

NPI 1750301503 · CMS profile ID 306772

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750301503?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750301503?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750301503?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1750301503?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $12,707.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $45.3310/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034614724 CMS
Astellas Pharma US Inc $1,000.0010/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034614731 CMS
Astellas Pharma US Inc $47.2710/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034586643 CMS
Astellas Pharma US Inc $146.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034591419 CMS
GlaxoSmithKline, LLC. $156.2203/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061462094 CMS
GlaxoSmithKline, LLC. $10,000.0003/21/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061463882 CMS
GlaxoSmithKline, LLC. $47.5003/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061464144 CMS
GlaxoSmithKline, LLC. $71.4502/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001670017 CMS
GlaxoSmithKline, LLC. $60.3702/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001670057 CMS
GlaxoSmithKline, LLC. $131.4202/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001670039 CMS
GlaxoSmithKline, LLC. $227.3602/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001670047 CMS
GlaxoSmithKline, LLC. $109.0602/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001670067 CMS
GlaxoSmithKline, LLC. $665.1402/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001670027 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $119.70 1
PY2023 $12,707.12 13
PY2024 $184.08 4
PY2025 $2,569.53 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,582.34 15
PY2025 Principal investigator $260,502.25 43
PY2024 Principal investigator $147,535.10 28
PY2023 Recipient $2,359.23 6
PY2023 Principal investigator $286,959.88 51
PY2022 Principal investigator $147,785.97 35
PY2021 Recipient $31,165.00 1
PY2021 Principal investigator $320,361.44 168
PY2020 Principal investigator $484,980.10 158
PY2019 Principal investigator $153,612.59 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Astellas Pharma Global Development $19,510.00 12/10/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects No dispute reported 06/30/2026 641393775
Principal investigator 1 Allergan Inc. $2,500.00 12/01/2019 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections No dispute reported 06/30/2026 670012019
Principal investigator 1 Gilead Sciences, Inc. $1,617.00 11/20/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384339
Principal investigator 1 ViiV Healthcare Company $1,349.76 11/14/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 669629735
Principal investigator 1 Gilead Sciences, Inc. $7,971.00 10/23/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384333
Principal investigator 1 Astellas US Technologies $315.39 10/05/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects No dispute reported 06/30/2026 638192301
Principal investigator 1 Astellas US Technologies $315.39 10/05/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects No dispute reported 06/30/2026 638192307
Principal investigator 1 Astellas US Technologies $315.39 10/05/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects No dispute reported 06/30/2026 638192311
Principal investigator 1 Astellas US Technologies $315.39 10/05/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects No dispute reported 06/30/2026 638192315
Principal investigator 1 Astellas US Technologies $315.39 10/05/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects No dispute reported 06/30/2026 638192317
Principal investigator 1 Astellas US Technologies $315.39 10/05/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects No dispute reported 06/30/2026 638192321
Principal investigator 1 Gilead Sciences, Inc. $2,408.00 09/18/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384325
Principal investigator 1 Gilead Sciences, Inc. $8,387.00 08/21/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384321
Principal investigator 1 Gilead Sciences, Inc. $4,947.00 07/17/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384317
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $12,600.00 06/25/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235939
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $1,260.00 06/25/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235941
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $3,780.00 06/25/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235943
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $1,592.64 06/25/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235945
Principal investigator 1 Gilead Sciences, Inc. $6,927.00 06/19/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384311
Principal investigator 1 ViiV Healthcare Company $562.83 05/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 669627059
Principal investigator 1 Gilead Sciences, Inc. $9,825.00 05/22/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384307
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192217
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192223
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192229
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192233
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192237
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192239
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192243
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192249
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192251
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192255
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192260
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192263
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192269
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192273
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192277
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192281
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192285
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192289
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192293
Principal investigator 1 Astellas US Technologies $315.39 05/21/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 638192297
Principal investigator 1 ViiV Healthcare Company $7,291.75 05/16/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 669627057
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $2,500.00 05/14/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235937
Principal investigator 1 Gilead Sciences, Inc. $6,615.00 05/06/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384301
Principal investigator 1 Gilead Sciences, Inc. $6,564.00 04/22/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384297
Principal investigator 1 Gilead Sciences, Inc. $454.00 03/20/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384293
Principal investigator 1 PFIZER INC. $987.47 03/06/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LOS ANGELES
A PROSPECTIVE OPENLABEL STUDY TO ASSESS THE PHARMACOKINETICS SAFETY EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS INCLUDING CANDIDEMIA No dispute reported 06/30/2026 671672273
Principal investigator 1 Gilead Sciences, Inc. $6,316.00 02/20/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384287
Principal investigator 1 Merck Sharp & Dohme Corporation $200.00 02/14/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old No dispute reported 06/30/2026 691322005
Principal investigator 1 Allergan Inc. $5,000.00 02/05/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A PHASE 3 MULTICENTER, OPEN-LABEL, RANDOMIZED, COMPARATOR CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF DALBAVANCIN VERSUS ACTIVE COMPARATOR IN PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS No dispute reported 06/30/2026 670012061
Principal investigator 1 ViiV Healthcare Company $874.45 02/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 669626393
Principal investigator 1 ViiV Healthcare Company $1,051.79 02/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 669626395
Principal investigator 1 ViiV Healthcare Company $8,244.28 02/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 669626397
Principal investigator 1 ViiV Healthcare Company $3,069.48 02/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 669626399
Principal investigator 1 Merck Sharp & Dohme Corporation $4,481.00 01/29/2019 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA MEDICAL CENTER
A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old No dispute reported 06/30/2026 691310839
Principal investigator 1 Gilead Sciences, Inc. $6,526.00 01/28/2019 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676384283